This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer (ONTAK)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Tyler Curiel, The University of Texas Health Science Center at San Antonio
ClinicalTrials.gov Identifier:
NCT00880360
First received: April 10, 2009
Last updated: January 7, 2013
Last verified: January 2013
Results First Received: August 13, 2012  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Conditions: Epithelial Ovarian Cancer
Extraovarian Peritoneal Cancer
Fallopian Tube Carcinoma
Intervention: Drug: Ontak

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Ontak Ontak : Patients will be treated with Ontak at 12 µg/kg monthly as long as they meet response criteria.

Participant Flow:   Overall Study
    Ontak
STARTED   19 
COMPLETED   19 
NOT COMPLETED   0 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Ontak Ontak : Patients will be treated with Ontak at 12 µg/kg monthly as long as they meet response criteria.

Baseline Measures
   Ontak 
Overall Participants Analyzed 
[Units: Participants]
 19 
Age 
[Units: Participants]
 
<=18 years   0 
Between 18 and 65 years   11 
>=65 years   8 
Age 
[Units: Years]
Mean (Standard Deviation)
 63  (1) 
Gender 
[Units: Participants]
 
Female   19 
Male   0 
Region of Enrollment 
[Units: Participants]
 
United States   19 


  Outcome Measures

1.  Primary:   Number of Participants Demonstrating Clinical Response   [ Time Frame: 2 years ]

2.  Secondary:   Toxicity   [ Time Frame: 3 years ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Dr. Tyler Curiel
Organization: University of Texas Health Science Center at San Antonio
phone: 210-450-1000
e-mail: curielt@uthscsa.edu



Responsible Party: Tyler Curiel, The University of Texas Health Science Center at San Antonio
ClinicalTrials.gov Identifier: NCT00880360     History of Changes
Obsolete Identifiers: NCT00238186
Other Study ID Numbers: HSC20070042H
OCR 07-04 ( Other Identifier: UTHSCSA )
Study First Received: April 10, 2009
Results First Received: August 13, 2012
Last Updated: January 7, 2013